HanchorBio Tests Broader Ambitions for HCB101 Through InxMed Partnership

Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist InxMed.TAIPEI and SHANGHAI and SAN FRANCISCO, July 8, 2026 /PRNewswire/ — HanchorBio, Inc. (TWSE: 7827) is taking…

Read the full release →

News provided by PR Newswire.